XML 30 R24.htm IDEA: XBRL DOCUMENT v3.25.1
Stockholders' Equity and Stock Options (Tables)
3 Months Ended
Mar. 31, 2025
Stockholders' Equity Note [Abstract]  
Assumptions used to Determine Fair Value of Stock Options Granted

The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees during the three months ended March 31, 2025:

 

 

 

March 31,

 

 

2025

Risk-free interest rate

 

4.47%

Expected term (in years)

 

6.25

Expected volatility

 

94%

Dividend yield

 

0.00%

 

Summary of Stock Option Activity

The following table summarizes the Company’s stock option activity for the three months ended March 31, 2025 (amounts in millions, except for share, contractual term, and per share data):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

Weighted Average

 

 

Aggregate

 

 

 

 

 

 

Average

 

 

Remaining

 

 

Intrinsic

 

 

 

Number of

 

 

Exercise

 

 

Contractual

 

 

Value (a)

 

 

 

Shares

 

 

Price

 

 

Term (in years)

 

 

(in millions)

 

Outstanding as of December 31, 2024

 

 

6,436,387

 

 

$

7.78

 

 

 

7.6

 

 

 

 

Options granted

 

 

2,130,437

 

 

 

3.45

 

 

 

 

 

 

 

Options forfeited/expired

 

 

(25,335

)

 

 

5.62

 

 

 

 

 

 

 

Outstanding as of March 31, 2025

 

 

8,541,489

 

 

$

6.71

 

 

 

7.9

 

 

$

 

Exercisable as of March 31, 2025

 

 

3,708,423

 

 

$

9.54

 

 

 

6.4

 

 

$

 

Vested and expected to vest as of March 31, 2025

 

 

8,541,489

 

 

$

6.71

 

 

 

7.9

 

 

$

 

(a)
The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were "in the money" at March 31, 2025.
Summary of Restricted Stock Units

Activity with respect to the Company's RSUs and performance-based RSUs during the three months ended March 31, 2025 was as follows (in millions, except share, contractual term, and per share data):

 

 

 

 

 

 

Weighted

 

 

Weighted Average

 

 

Aggregate

 

 

 

 

 

 

Average

 

 

Remaining

 

 

Intrinsic

 

 

 

Number of

 

 

Grant Date

 

 

Contractual

 

 

Value (a)

 

 

 

Shares

 

 

Fair Value

 

 

Term (in years)

 

 

(in millions)

 

Outstanding as of December 31, 2024

 

 

699,003

 

 

$

4.69

 

 

 

1.2

 

 

 

 

Restricted stock units granted

 

 

544,988

 

 

 

3.46

 

 

 

 

 

 

 

Restricted stock units vested

 

 

(212,827

)

 

 

4.73

 

 

 

 

 

 

 

Restricted stock units forfeited

 

 

(8,103

)

 

 

4.80

 

 

 

 

 

 

 

Outstanding as of March 31, 2025

 

 

1,023,061

 

 

$

4.02

 

 

 

1.9

 

 

$

2.2

 

Unvested and expected to vest as of March 31, 2025

 

 

1,023,061

 

 

$

4.02

 

 

 

1.9

 

 

$

2.2

 

Summary of Stock-Based Compensation Expense

Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows:

 

 

 

Three Months Ended March 31,

 

 

 

2025

 

 

2024

 

Research and development

 

$

926

 

 

$

911

 

General and administrative

 

 

908

 

 

 

1,217

 

 

$

1,834

 

 

$

2,128